ICCC vs XLV
ImmuCell Corporation (ICCC) versus Health Care Select Sector SPDR® Fund (XLV) — a side-by-side from cached financials, not a winner call.
ImmuCell Corporation (ICCC) is a biotechnology company listed on US.
Health Care Select Sector SPDR® Fund (XLV) common stock listed on US.
Latest reported ICCC revenue for 2026-06-30 was $17.5M. Net income was $3.8M. Revenue was up 69.4% from 2026-03-31 to 2026-06-30. ICCC currently screens at market cap $58.9M.
XLV does not have a complete income-statement cache yet.
ICCC currently screens at market cap $58.9M. XLV currently screens at market cap $0.
Not investment advice. Open the ICCC and XLV stock pages for the full models.
Not investment advice.